razoxane has been researched along with Heart Failure in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 10 (35.71) | 18.2507 |
| 2000's | 11 (39.29) | 29.6817 |
| 2010's | 6 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brower, V | 1 |
| Bosso, G; Ceste, M; de Conciliis, E; Ferrero, G; Ferro, S; Giaretto, L; Lanfranco, C; Manfredi, R; Miglietta, L; Milanese, S; Parello, G; Simoni, C; Testore, F | 1 |
| Beijnen, JH; Goey, AK; Huitema, AD; Schellens, JH | 1 |
| Ahn, HS; Choi, HS; Choi, JY; Kang, HJ; Noh, CI; Park, ES; Shin, HY; Yun, YS | 1 |
| Anderson, P; Chandra, J; Fulbright, JM; Huh, W | 1 |
| Balis, FM; Ginsberg, JP; Sepe, DM | 1 |
| Cunningham, D; Hawkes, EA; Okines, AF; Plummer, C | 1 |
| Al-Khadimi, Z; Chow, WA; Doroshow, JH; Frankel, P; Lawrence, J; Leong, L; Lim, D; Longmate, J; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Synold, TW; Tetef, ML; Twardowski, P; Yen, Y | 1 |
| de Vries, EG; Perik, PJ; van den Berg, MP; van Veldhuisen, DJ | 1 |
| Adamcová, M; Gersl, V; Hrdina, R; Kaplanová, J; Klimtová, I; Mazurová, Y; Simůnek, T; Sterba, M | 1 |
| Pouillart, P | 1 |
| Elbl, L; Hrstkova, H; Michalek, J; Tomaskova, I | 1 |
| Bernitsas, E; Mikol, DD; Wei, W | 1 |
| De Giorgi, U; Emiliani, E; Frassineti, L; Giannini, M; Giovannini, N; Kopf, B; Marangolo, M; Palazzi, S; Rosti, G; Zumaglini, F | 1 |
| Lipshultz, SE | 1 |
| Bosnjak, S; Jelić, S; Kreacić, M; Milanović, N; Nesković-Konstantinović, Z; Radulović, S; Ristović, Z; Vuletić, L | 1 |
| Garin, AM; Lichinitser, MP; Min'kov, ED; Nakhalova, TA; Odzharova, AA; Vyshinskaia, GV | 1 |
| Bianchine, JR; Desai, A; Ewer, MS; Gams, RA; Gerber, MC; Jones, SE; Mittelman, A; Pendergrass, K; Reddy, S; Speyer, J; Spicer, D; Swain, SM; Velez-Garcia, E; Vogel, C; Wadler, S; Weisberg, S; Whaley, FS; York, M | 1 |
| Bianchine, JR; Ewer, MS; Gams, RA; Gerber, MC; Swain, SM; Whaley, FS | 1 |
| Swain, SM | 1 |
| Bramwell, V; Moran, LA; Seymour, L | 1 |
| Bengala, C; Carnino, F; Conte, P; Del Mastro, L; Gallo, L; Lionetto, R; Michelotti, A; Montanaro, E; Rosso, R; Tibaldi, C; Venturini, M | 1 |
| Carlson, RW | 1 |
| Creighton, AM; Hopewell, JW; Jaenke, RS; Wilding, D; Yeung, TK | 1 |
| Ferrans, V; Green, MD; Hochster, H; Kramer, E; Meyers, M; Rey, M; Sanger, J; Speyer, JL; Wernz, JC; Zeleniuch-Jacquotte, A | 1 |
| Dubin, N; Ferrans, V; Green, MD; Kramer, E; Rey, M; Sanger, J; Speyer, JL; Stecy, P; Ward, C; Zeleniuch-Jacquotte, A | 1 |
4 review(s) available for razoxane and Heart Failure
| Article | Year |
|---|---|
[Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Topics: Anthracyclines; Cardiovascular Agents; Heart Diseases; Heart Failure; Humans; Randomized Controlled Trials as Topic; Razoxane | 2010 |
Can anthracycline therapy for pediatric malignancies be less cardiotoxic?
Topics: Adolescent; Adult; Anthracyclines; Child; Delayed-Action Preparations; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Carriers; Drug Dosage Calculations; Drug-Related Side Effects and Adverse Reactions; Heart; Heart Diseases; Heart Failure; Humans; Iron Chelating Agents; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Razoxane; Risk Factors; Treatment Outcome | 2010 |
Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
Topics: Adult; Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cardiotonic Agents; Child; Heart Failure; Humans; Razoxane | 2004 |
Exposure to anthracyclines during childhood causes cardiac injury.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Agents; Cardiomyopathies; Cardiovascular Agents; Child; Disease Progression; Heart; Heart Failure; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Razoxane; Risk Factors; Survivors | 2006 |
10 trial(s) available for razoxane and Heart Failure
| Article | Year |
|---|---|
Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.
Topics: Adolescent; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Cohort Studies; Disease-Free Survival; Doxorubicin; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Infant; Male; Neoplasms; Razoxane; Ventricular Function, Left | 2010 |
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Topics: Adult; Antibiotics, Antineoplastic; Cardiovascular Agents; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Heart Failure; Humans; Infusions, Intravenous; Levofloxacin; Male; Middle Aged; Neoplasms; Neutropenia; Ofloxacin; Razoxane; Sarcoma; Sepsis; Treatment Outcome | 2004 |
Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
Topics: Adolescent; Adult; Anthracyclines; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Echocardiography; Female; Follow-Up Studies; Heart Failure; Hematologic Neoplasms; Humans; Male; Razoxane; Retrospective Studies; Stroke Volume; Survival Analysis; Treatment Outcome | 2006 |
Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.
Topics: Adult; Animals; Antineoplastic Agents; Cardiovascular Agents; Female; Heart Failure; Humans; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis; Razoxane; Stroke Volume; Troponin I | 2006 |
Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Epirubicin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Heart Failure; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation Pneumonitis; Radiodermatitis; Razoxane; Recombinant Proteins | 2006 |
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cyclophosphamide; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Fluorouracil; Heart Failure; Humans; Prospective Studies; Razoxane; Risk Factors; Survival Analysis; Treatment Outcome | 1997 |
Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cyclophosphamide; Disease-Free Survival; Double-Blind Method; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Heart Failure; Humans; Middle Aged; Prospective Studies; Razoxane; Treatment Outcome | 1997 |
Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Cardiovascular Agents; Epirubicin; Female; Heart Failure; Humans; Injections, Intravenous; Middle Aged; Razoxane; Treatment Outcome; Ventricular Dysfunction, Left | 2000 |
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Heart Failure; Humans; Life Tables; Middle Aged; Razoxane; Regression Analysis; Survival Analysis; Ventricular Function, Left | 1992 |
Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Tolerance; Female; Fluorouracil; Heart; Heart Failure; Humans; Middle Aged; Myocardium; Piperazines; Radionuclide Imaging; Random Allocation; Razoxane; Stroke Volume | 1988 |
14 other study(ies) available for razoxane and Heart Failure
| Article | Year |
|---|---|
Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cardiotonic Agents; Chelating Agents; Female; Heart; Heart Failure; Humans; Molecular Targeted Therapy; Razoxane; Receptor, ErbB-2; Stroke Volume; Trastuzumab | 2013 |
Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Dose-Response Relationship, Drug; Doxorubicin; Electrocardiography; Epirubicin; Female; Follow-Up Studies; Heart Failure; Humans; Incidence; Life Expectancy; Middle Aged; Neoplasm Metastasis; Razoxane; Retrospective Studies | 2008 |
Dexrazoxane: a second look. Prevention of anthracycline cardiotoxicity: useful for some patients.
Topics: Anthracyclines; Chemotherapy, Adjuvant; Drug Approval; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; France; Heart Failure; Humans; Meta-Analysis as Topic; Razoxane | 2008 |
Dexrazoxane as a cardioprotectant in children receiving anthracyclines.
Topics: Adolescent; Anthracyclines; Antineoplastic Agents; Arrhythmias, Cardiac; Cardiomyopathies; Cardiotonic Agents; Child; Child, Preschool; Heart Failure; Humans; Razoxane; Risk Factors; Treatment Outcome; Young Adult | 2010 |
Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Labeling; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Heart Failure; Humans; Lymphoma, Large B-Cell, Diffuse; Meta-Analysis as Topic; Paclitaxel; Prednisone; Razoxane; Remission, Spontaneous; Rituximab; Trastuzumab; Vincristine | 2011 |
Experimental animal model for anthracycline-induced heart failure.
Topics: Animals; Anthracyclines; Body Weight; Cardiovascular Agents; Disease Models, Animal; Heart Failure; Heart Rate; Models, Cardiovascular; Razoxane; Stroke Volume | 2004 |
Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Biomarkers; Body Weight; Cardiovascular Agents; Daunorubicin; Disease Models, Animal; Dose-Response Relationship, Drug; Echocardiography; Erythrocyte Indices; Heart Failure; Heart Rate; Heart Ventricles; Male; Models, Cardiovascular; Myocardium; Myocytes, Cardiac; Rabbits; Razoxane; Stroke Volume; Time Factors | 2004 |
Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Doxorubicin; Echocardiography; Electrocardiography; Female; Fluorouracil; Heart; Heart Failure; Humans; Infusions, Intravenous; Lymphatic Metastasis; Middle Aged; Razoxane; Remission Induction; Risk Factors; Stroke Volume; Ventricular Function, Left | 1995 |
New drug counters doxorubicin cardiotoxicity; not for use at start of chemotherapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Heart; Heart Failure; Humans; Razoxane | 1995 |
[Cardioxan as a cardioprotector in antineoplastic chemotherapy].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Heart; Heart Failure; Humans; Radionuclide Ventriculography; Razoxane; Treatment Outcome | 1996 |
Doxorubicin-induced cardiomyopathy.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cardiovascular Agents; Doxorubicin; Heart Failure; Humans; Razoxane | 1999 |
Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Epirubicin; Evidence-Based Medicine; Female; Heart; Heart Failure; Humans; Neoplasms; Odds Ratio; Randomized Controlled Trials as Topic; Razoxane; Time Factors; Treatment Outcome | 1999 |
Reducing the cardiotoxicity of the anthracyclines.
Topics: Antibiotics, Antineoplastic; Biopsy, Needle; Endocardium; Heart Diseases; Heart Failure; Heart Function Tests; Humans; Myocardium; Neoplasms; Razoxane; Risk Factors; Sensitivity and Specificity | 1992 |
The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat.
Topics: Animals; Body Weight; Cardiac Output; Dose-Response Relationship, Drug; Doxorubicin; Heart; Heart Diseases; Heart Failure; Heart Rate; Hemorrhage; Male; Pleural Effusion; Rats; Rats, Inbred Strains; Razoxane; Time Factors | 1992 |